SEC Filing Summary for BRAINSTORM CELL THERAPEUTICS INC.

Jacob A. Frenkel, a director at BRAINSTORM CELL THERAPEUTICS INC. (BCLI), acquired 100,000 shares of restricted stock units (RSUs) on July 24, 2026. These RSUs were issued under a Consulting Agreement and are subject to the 2014 Global Share Option Plan. The RSUs will vest in two tranches: 50% on October 24, 2026, and the remaining 50% on April 24, 2027, provided that Mr. Frenkel continues to provide services to the company. The acquisition was made pursuant to a consulting agreement, with no monetary price paid per share (transaction price of $0.00). Following this transaction, Mr. Frenkel holds 343,777 shares. The filing is Form 4, indicating a change in beneficial ownership.